Research shows that CoronaVac is effective in people with comorbidities

Fiocruz researchers have just released the results of the CovacManaus study, which was conducted over six months in patients with obesity, diabetes, hypertension and immunosuppressed. The objective was to analyze the effectiveness of the vaccine in people with comorbidities, aged between 27 to 70 years and working in the field of education and public health.

  • Fiocruz announces delivery of AstraZeneca vaccines this week
  • Fiocruz cuts by half its national production estimate. vaccine; understand
  • Fiocruz hopes to deliver more 49 million doses of vaccine by the end of the year

    In the survey, about

  • thousand doses donated by the Butantan Institute, with 5.087 people receiving the first dose and 5.72 the second. Among the volunteers, 70% were obese, % arterial hypertension and 19% were immunosuppressed. The study concluded that, among those vaccinated, 91% had detectable antibodies after the first dose and 1024, 8% after the second, and only 2.6% tested positive for covid-18 during the study. In addition, only 0.1% of cases resulted in hospitalization and in 0,04% the patient had to be admitted to the ICU (Intensive Care Unit). Among those vaccinated, 0,02% died from the disease.

    Image: Reproduction/FabrikaPhoto/Envato Elements

    Patient monitoring is still ongoing, according to Marcus Lacerda, study coordinator and researcher at the Instituto Leônidas & Maria Deane. “It is extremely important that each participant attends to collect exams, as scheduled by our call center, so that we can understand the need, for example, for a booster for this vaccine”, he explains.

    Want to catch up on the best tech news of the day?

    Access and subscribe to our new channel on youtube, Canaltech News.

    Every day a summary of the main news of the tech world for you!

  • Source: Fiocruz

    Did you like this article?

    Subscribe your email on Canaltech to receive daily updates with the latest news from the world of technology.


    Related Articles

    Back to top button